Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

2,414

Participants

Timeline

Start Date

September 6, 2019

Primary Completion Date

September 3, 2020

Study Completion Date

September 3, 2020

Conditions
InfluenzaHumanVirus Diseases
Interventions
BIOLOGICAL

QIVc

Previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1; not previously vaccinated subjects received a 0.5 mL intramuscular dose of QIVc on Day 1 and Day 29.

BIOLOGICAL

Comparator QIV

Previously vaccinated subjects received a dose of Comparator QIV on Day 1; not previously vaccinated subjects received a dose of Comparator QIV on Day 1 and Day 29. Subjects 6 months through 35 months of age received a 0.25 mL intramuscular dose of Comparator QIV; subjects 36 months through 47 months of age received a 0.5 mL intramuscular dose of Comparator QIV.

Trial Locations (47)

13901

84013 Regional Clinical Research, Binghamton

22902

84039 Pediatric Research of Charlottesville, Charlottesville

30341

84052 Tekton Research, Chamblee

33054

84005 Sunshine Research Center, Opa-locka

33142

84001 Acevedo Clincal Research Associates, Miami

36608

84035 CCR Research, Mobile

37203

84032 Clinical Research Associates, Nashville

39503

84053 MedPharmics, Gulfport

40004

84041 Kentucky Pediatric/ Adult Research, Bardstown

40291

84009 Bluegrass Clinical Research Inc., Louisville

45406

84045 Dayton Clinical, Dayton

45419

84003 PriMed Clinical Research, Dayton

57049

84015 Meridian Clinical Research, Dakota Dunes

63044

84051 Office of Craig A. Spiegel, Bridgeton

64114

84016 Center for Pharmaceutical Research, Kansas City

67042

84027 Heartland Research Associates, El Dorado

67114

84020 Heartland Research Associates, Newton

67205

84014 Heartland Research Associates, Wichita

67207

84026 Heartland Research Associates, Wichita

68116

84017 Meridian Clinical Research, Omaha

68701

84037 Meridian Clinical Research, Norfolk

70006

84004 Benchmark Research, Metairie

84022 Med Pharmics, Metairie

70806

84008 Meridian Clinical Research, Baton Rouge

71037

84046 ACC Pediatric Research, Haughton

76104

84023 Ventavia Research Group, Fort Worth

76107

84042 Universtiy of North Texas Health Science Center, Fort Worth

76135

84043 Benchmark Research, Fort Worth

76248

84019 Ventavia Research Group, Keller

76904

84021 Benchmark Research, San Angelo

77008

84047 Ventavia Research Group, Houston

77055

84011 West Houston Clinical Research, Houston

77375

84025 Pediatric Healthcare of NW Houston, Tomball

78240

84002 Tekton Research, San Antonio

78705

84007 Benchmark Research, Austin

83642

84036 Advanced Clinical Research, Meridian

84041

84018 Tanner Clinic, Layton

84088

84031 Advanced Clinical Research, West Jordan

84107

84050 JBR Clinical Research Group, Salt Lake City

84121

84048 J. Lewis Research/Foothill Family Clinic South, Salt Lake City

87102

84033 Med Pharmics, Albuquerque

90240

84044 Premier Health Research Center, Downey

90723

84029 Center for Clinical Trials, Paramount

91763

84028 Orange County Research Institute, Ontario

92804

84040 Southland Clnical Research Center, Anaheim

95864

84012 Benchmark Research, Sacramento

92123-1881

84006 California Research Foundation, San Diego

All Listed Sponsors
lead

Seqirus

INDUSTRY

NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects | Biotech Hunter | Biotech Hunter